Recursion Pharmaceuticals, Inc. RXRX Business Segments — Operating Income (Loss)
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s business segments — operating income (loss).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s business segments — operating income (loss)?
- Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — operating income (loss) of -$128.51M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s business segments — operating income (loss) changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s business segments — operating income (loss) increased by 32.8% year-over-year, from -$191.37M to -$128.51M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — operating income (loss)?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — operating income (loss) has grown at a 38.2% compound annual growth rate (CAGR), from -$245.73M to -$648.13M.
- What does business segments — operating income (loss) mean?
- Calculated as the segment's total revenue minus its direct operating expenses, representing the profitability of the business segment before interest and taxes. This is the primary measure of the segment's operational efficiency and its ability to generate value from its core activities.